Recurrence-Free Survival Endpoint

Definition

Recurrence-free survival is an oncology trial endpoint that measures how long patients remain free of cancer recurrence after treatment in a setting where visible disease has been removed or controlled.

Current Synthesis

E250｜mRNA的第二战场：对话英博，拆解Moderna人类首个肿瘤疫苗三期突破 makes recurrence-free survival central to interpreting InterPath001. The episode says the Moderna/Merck individualized vaccine plus PD-1 arm reached statistical significance against PD-1 alone in postoperative later-stage melanoma patients.

The same source distinguishes recurrence-free survival from progression-free survival. In the episode’s framing, postoperative no-recurrence means the patient has no visible tumor state after surgery, while progression-free survival is more natural when measurable disease is already present and treatment tries to delay growth or spread. Neither endpoint automatically proves overall survival, so HR, subgroups, total survival, approval status, and patient access remain open.

Key Claims

• RFS is most legible in postoperative or adjuvant settings where the clinical question is whether cancer returns.
• RFS should not be casually merged with PFS because PFS usually concerns progression of existing disease.
• A positive RFS result can be clinically meaningful while still leaving OS unresolved.
• Endpoint interpretation depends on trial design, patient population, comparator treatment, HR, subgroup data, and follow-up maturity.
• For individualized vaccines, RFS matters because the intended job is often to help clear residual microscopic disease after surgery.

Evidence

• InterPath001 readout: E250｜mRNA的第二战场：对话英博，拆解Moderna人类首个肿瘤疫苗三期突破 says the trial’s main endpoint is recurrence-free survival and the combination arm reached statistical significance.
• Endpoint distinction: E250｜mRNA的第二战场：对话英博，拆解Moderna人类首个肿瘤疫苗三期突破 explicitly distinguishes postoperative no-recurrence from progression-free survival.
• Evidence boundary: E250｜mRNA的第二战场：对话英博，拆解Moderna人类首个肿瘤疫苗三期突破 says HR and subgroup data remain undisclosed in the episode.

Counterevidence & Qualifications

This concept does not say RFS is unimportant or sufficient by itself. It records the endpoint boundary: RFS can validate recurrence-delay claims in a designed trial, but overall survival, quality of life, adverse effects, cost, and access may still change the clinical judgment.

What Changed

• Created an endpoint page to keep InterPath001’s recurrence-free-survival signal distinct from progression-free and overall-survival claims.

Related Concepts

• Progression-Free vs Overall Survival - adjacent endpoint distinction for PFS and OS.
• Clinical Development Capability - trial design and endpoint interpretation capability.
• Individualized Cancer Vaccine - therapy whose postoperative value is evaluated through recurrence.
• InterPath001 - trial that grounds this page.
• Medical Risk Management - patient-level risk-benefit frame around endpoint interpretation.